Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Wave Life Sciences Ltd. Ordinary Shares

WVE

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Last trade $2.86
Day change -$0.01 (-0.35%)
Day range $2.79 – $3.00
Volume 1,738,343
Market cap $566M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$566.05M
Price / earnings
—
Price / book
1.41×
Price / sales
7.98×
EV / sales
5.2×
EV / EBITDA
-1.64×

Profitability

Earnings per share
-$1.07
Return on assets
-41.45%
Return on equity
-52.38%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.38×
Quick ratio
8.38×
Cash ratio
3.6×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$208.39M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for WVE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$13.16M$2.27M$38.25M$17.25M$7.61M$8.7M$9.18M$83.75M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$13.16M$2.27M$38.25M$17.25M$7.61M$8.7M$9.18M$83.75M
Selling, general and administrative$25.36M$24.78M$22.1M$20.9M$18.09M$17.99M$18.36M$16.14M
Research and development$53.84M$51.29M$47.44M$52.81M$45.87M$43.47M$40.62M$44.65M
Total operating expenses$79.21M$76.07M$69.54M$73.71M$63.96M$61.46M$58.98M$60.78M
Operating income-$66.05M-$73.8M-$31.3M-$56.47M-$56.35M-$52.76M-$49.8M$22.97M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$61.91M-$69.36M-$26.09M-$53.18M-$53.85M-$50.47M-$46.88M$29.25M
Income taxes$0$0$0$0$0$0$0$0
Net income-$61.91M-$69.36M-$26.09M-$53.18M-$53.85M-$50.47M-$46.88M$29.25M
Net income attributable to common shareholders-$61.91M-$69.36M-$26.09M-$53.18M-$53.85M-$50.47M-$46.88M$29.25M
EBITDA-$65.17M-$72.94M-$30.46M-$55.62M-$55.5M-$51.89M-$48.93M$23.87M
Basic earnings per share-$0.30-$0.34-$0.13-$0.29-$0.32-$0.31-$0.29$0.18
Diluted earnings per share-$0.30-$0.34-$0.13-$0.29-$0.32-$0.31-$0.29$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for

GSK is expected to report a year-over-year earnings decline of 5.4% to $1.40 per share for Q3 2026, despite revenues rising 2.4% to $11.8 billion. With a negative Earnings ESP of -4.56% and Zacks Rank #4, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten estimates in recent quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.

GlobeNewswire Inc.

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

GlobeNewswire Inc.

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

Benzinga

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

Wave Life Sciences regained full rights to WVE-006 from GSK for treating alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder. Wave plans to accelerate the registrational strategy and pursue an accelerated FDA approval pathway, with regulatory feedback expected mid-2026. Clinical trial data from the RestorAATion-2 trial is on track for Q1 2026. WVE stock rose 4.48% on the announcement.

Investing.com

Golden Cross Alert: 3 Stocks With Major Upside Potential

The article highlights three stocks showing potential for upside momentum in 2026 based on golden cross technical signals and fundamental analysis: Sun Communities, Darling Ingredients, and Wave Life Sciences.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.